Table 1.
Baseline characteristics of included studies
| Study | Country | Study center | Recruiting window | Control disease | ITC number (%) | Age (years) | Female (%) | NOS |
|---|---|---|---|---|---|---|---|---|
| Dobyns et al,27 1974 | America | Multicenter | 1946–1968 | TA, unclassified | 50 (0.43) | NR | NR | 7 |
| Kunjumohamed et al,28 2015 | Oman | Single center | 2007–2013 | TA, TMG | 23 (32.39) | 17–76 | 59 (83.1) | 7 |
| Linos et al,29 1997 | Greece | Single center | 1982–1991 | TNG, TN | 27 (6.75) | 39 | 338 (84.5) | 5 |
| Mittenforf and McHenry,30 2001 | America | Single center | 1990–1998 | Thyroiditis, TMG | 6 (11.11) | 42 | 44 (80) | 7 |
| Ocak et al,31 2014 | Turkey | NR | 2005–2010 | TMG, UTG | 13 (7.34) | 45.9 | 134 (75.7) | 5 |
| Pradeep et al,32 2007 | India | Single center | 1990–2005 | TMG | 19 (5.85) | 39.86 | 249 (76.7) | 7 |
| Ruggieri et al,33 1999 | Italy | Single center | 1994–1999 | TMG, autonomous nodule | 6 (7.32) | 52 | 60 (73) | 7 |
| Terzioglu et al,34 1993 | Italy | Single center | 1986–1991 | TNG, TA | 8 (5.80) | 43.1 | NR | 5 |
| Wahl et al,35 1982 | Germany | Multicenter | 1962–1979 | TMG, UTG | 18 (2.56) | NR | NR | 7 |
| Zanella et al,36 2001 | Italy | Single center | NR (20 years) | TMG, TA | 12 (6.06) | 53.5 | 148 (73.2) | 8 |
| Quérat et al,37 2015 | France | Single center | 2004–2012 | TMG, amiodarone | 25 (12.50) | 55.7 | 33 (80.5) | 7 |
Abbreviations: ITC, incidental thyroid carcinoma; NOS, Newcastle–Ottawa scale; TA, toxic adenoma; TMG, toxic multinodular goiter; TNG, toxic nodular goiter; TN, toxic nodule; UTG, toxic uninodular goiter; NR, not reported.